Featured Story | By Annalee Armstrong Ovid Therapeutics CEO Jeremy Levin had a difficult choice to make in shedding the company's lead Angelman syndrome asset OV101, but a recent deal with Takeda at least took financing out of the equation. read more |
| |
|---|
|
Top Stories By Amirah Al Idrus Just two months after launching with $250 million, four clinical programs and a deep bench of earlier-stage prospects, Centessa Pharmaceuticals is aiming for the public markets. The company filed on Wednesday to raise up to $100 million in its Nasdaq IPO, but, if recent deals are any indication, it will likely rake in considerably more. read more By Annalee Armstrong Brand-new biotech Anavo Therapeutics knows Big Pharma has been burned by a so-called undruggable target called phosphatases, but it's here to help now. read more Sponsored By: Catalent Cell & Gene Therapy Working with the right integrated partner can help ease increasingly common problems with scale, access to high-demand raw material, viral vector production and quality requirements. read more By Amirah Al Idrus Vertex Pharmaceuticals is inking another gene-editing deal, days after retooling a partnership with CRISPR Therapeutics to the tune of $900 million. This time, the company is teaming up with Obsidian Therapeutics to discover new gene-editing treatments that can be controlled with small molecules. read more By Amirah Al Idrus Companies are trying all kinds of combinations to make checkpoint inhibitors work for more people, including pairing them with cancer-killing viruses, engineered cytokines or even other checkpoint blockers. Medicxi’s latest bet is Monopteros, a biotech working on a treatment to reprogram T cells in the tumor microenvironment to jump-start an immune attack in cancer patients who otherwise would not respond to checkpoint inhibitors. read more By Angus Liu Scientists at the Albert Einstein College of Medicine have shown that a drug designed to invigorate a cellular garbage disposal mechanism ameliorated symptoms in two mouse models of Alzheimer’s disease. Some members of the team have cofounded a startup called Selphagy Therapeutics to move it forward. read more By Angus Liu Scientists at AstraZeneca have early data showing that an experimental antibody drug increases "good" HDL cholesterol in monkeys and people. Combining the drug with a PCSK9 inhibitor appeared to have a synergistic effect. read more Resources Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process intesification Sponsored By: August Bioservices How has COVID-19 impacted CRO/CDMO customer (dis)satisfaction and outsourcing decisions for pharma and biotech companies in 2021 and beyond? Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored by: PerkinElmer Informatics Discover the benefits of a cloud-native ELN that delivers better performance, security, connectivity, total cost of ownership PLUS sub-second search results through even the largest data volumes. Sponsored by: PulsePoint Access this guide for the latest insights into how marketers can use data, technology, and personalized messaging to build vaccine confidence and drive successful immunization efforts. Sponsored By: Within3 We enable virtual work — offering over-time sessions where participants are more focused, insights are more diverse and business goals are met. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: TAC Roche has inked a $1.8 billion, all-cash deal for GenMark Diagnostics, to acquire its molecular tests designed to screen patient samples for multiple infections simultaneously. Sponsored By: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. Sponsored By: Culture Biosciences Find out how upstream bioprocess scientists can use Culture Biosciences’ bioreactor system and real-time data visualizations to get faster insights and get their product to market more quickly. Sponsored By: BC Platforms Those wishing to unlock RWD’s true value must have access to a variety of data sources/types and the technological capabilities to use the data to uncover meaningful insights. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: Catalent Autologous cell therapies have seen propelled growth since 2017, with the spotlight on the first FDA approval of a chimeric antigen receptor (CAR) T cell immunotherapy, Kymriah® (tisagenlecleucel), for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. | 
